In addition, the 2022 American College of Cardiology/American Heart Association/Heart Failure Association of America Guideline for the Management of Heart Failure [21] recommends SGLT2 inhibition for patients because it has been shown to decrease the risk of hospitalization for heart failure and cardiovascular mortality in patients with heart failure, regardless of whether they have type 2 diabetes. This evidence concerns the gene SLC5A2 and heart failure.